Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 441.55B P/E 34.46 EPS this Y 7.50% Ern Qtrly Grth -
Income 19.17B Forward P/E 16.54 EPS next Y 3.20% 50D Avg Chg 5.00%
Sales 85.65B PEG 2.63 EPS past 5Y 5.44% 200D Avg Chg 3.00%
Dividend 3.00% Price/Book 5.87 EPS next 5Y 5.23% 52W High Chg -6.00%
Recommedations 2.30 Quick Ratio - Shares Outstanding 2.41B 52W Low Chg 13.00%
Insider Own 0.09% ROA - Shares Float 2.40B Beta 0.53
Inst Own 71.20% ROE - Shares Shorted/Prior 16.56M/15.84M Price 169.91
Gross Margin 69.33% Profit Margin 47.37% Avg. Volume 7,935,243 Target Price 173.75
Oper. Margin 28.80% Earnings Date Jul 17 Volume 14,213,937 Change 0.60%
About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.

Johnson & Johnson News
11:53 AM Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
09:23 AM Johnson & Johnson Is a King of Dividend Safety
06:01 AM Johnson & Johnson's (NYSE:JNJ) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
04/28/24 Dividend Stock Portfolio For Income: Top 15 Stocks
04/28/24 2 Top Growth Stocks to Buy Right Now and Hold Forever
04/28/24 Better Dividend Stock: AbbVie or Johnson & Johnson?
04/27/24 10 Best Long Term Low Risk Stocks to Buy
04/27/24 Johnson & Johnson Stock: Buy, Sell, or Hold?
04/26/24 AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
04/26/24 Are You Looking for a High-Growth Dividend Stock?
04/26/24 5 Stocks in Focus on Their Recent Dividend Hike
04/25/24 Cidara buys back rights to flu therapy from J&J for $85m
04/25/24 Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.24
04/24/24 Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
04/24/24 The Zacks Analyst Blog Highlights KB Home, Interactive Brokers Group, Qualcomm and Johnson & Johnson
04/24/24 These Are the 10 High-Profile Stocks U.S. Politicians Have Gravitated to Most Over the Last 3 Years
04/24/24 Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
04/24/24 14 Dividend Growth Stocks with Highest Growth Rates
04/23/24 Johnson & Johnson Children's Cough Syrup Contaminated In Some Batches - WHO Poised to Issue Global Alert (Updated)
04/23/24 Warning! These 3 Blue-Chip Stocks Will Have You Seeing Red
JNJ Chatroom

User Image GexPulse Posted - 1 hour ago

$JNJ Stock Analysis Current Price: $146.83. Positioned near the gamma flip at $142, suggesting increased volatility ahead. The 50-day SMA ($147.65) and 200-day SMA ($151.44) highlight resistance zones, with the current price below these levels indicating a potential bearish trend. Volume Point of Control at $156.18 marks significant resistance, while dynamic support and resistance converge at $158.16, emphasizing a strong barrier. Gamma Exposure with a Net GEX of 0.44 underlines market stability, but a bearish sentiment is echoed by a Put/Call Ratio of 1.37. Expected short-term moves are between $148.23 (upside) and $145.43 (downside). The narrow expected move range on a 1-hour timeframe points to possible consolidation. High Volume Nodes are identified at $158.16 and $156.71, suggesting these as critical resistance levels for near-term trading strategies. Stay tuned for pivotal movements and adjust strategies based on resistance breakouts or supports tested. https://twitter.com/GexPulse/status/1785044537368342720?t=VEsJJjzZFuDeRonwPL3gyA&s=19

User Image DonCorleone77 Posted - 7 hours ago

$JNJ J&J receives positive CHMP opinion recommending approval of Sirturo in MDR TB Johnson & Johnson announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of a Type II variation for SIRTURO and the conversion of the medicine's Conditional Marketing Authorisation into a standard Marketing Authorization. SIRTURO is currently indicated for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis in adult and pediatric patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. The positive CHMP recommendation is supported by data from the Phase 3 STREAM Stage 2 study, the first large-scale, randomized, multi-country clinical study to evaluate the efficacy and safety of an all-oral bedaquiline-containing regimen for treatment of MDR-TB. Results from the study showed bedaquiline-containing regimens offered a significant improvement over other therapies, confirm the positive risk-benefit of treatment with bedaquiline and were published in The Lancet in November 2022. SIRTURO was first granted accelerated approval by the U.S. Food and Drug Administration in December 2012 and conditional approval by the EMA in March 2014 following positive Phase 2 study data. In addition to the Type II variation filed with EMA, a supplemental New Drug Application was submitted to the FDA in August 2023 to support the transition to full approval in the U.S., and is currently under review.

User Image underdemeciated Posted - 7 hours ago

$AZN $PFE $JNJ I mean if everyone is dead how would they know . Such a sad world we live in. Don't trust pharma. https://www.dailymail.co.uk/health/article-13361271/AstraZeneca-admits-Covid-vaccine-cause-rare-blood-clotting-effect-legal-fight-victims-defective-jab.html

User Image EWavePlayer Posted - 8 hours ago

$LABU A lot of analysis posted here today, much to the same conclusion: Buckle Up. $XBI $IBB $MRK $JNJ

User Image Outcomes Posted - 10 hours ago

$PFE $MRNA $JNJ $AZN $NRXP ...and just one more piece of Monday morning news as the science, data, and results continue to be reported. Clinical trials matter. #Outcomesmatter Save the children. 🙏 https://open.substack.com/pub/2ndsmartestguyintheworld/p/landmark-new-publication-the-forgotten?r=re3i2&utm_medium=ios

User Image knightmoney26 Posted - 11 hours ago

$JNJ 150 this week?

User Image Outcomes Posted - 11 hours ago

$PFE $MRNA $JNJ $AZN $NRXP 'COVID vaccines are a disaster and that the medical community is looking the other way' Beware Bureaucrats. Beware Big pharma. Viral Vector. Mucosal immunity. BriLife. https://kirschsubstack.com/p/the-easiest-way-to-show-the-covid?r=re3i2&utm_medium=ios&triedRedirect=true

User Image FrnkTss Posted - 1 day ago

$JNJ 150 is the spot to watch for now if it breaks https://youtu.be/Yo2RgC0t3qU

User Image Stocksrunner Posted - 1 day ago

Sunday Coffee & Stocks: $ABBV vs $JNJ - Which Pharma Pays You Better? https://stocksrunner.com/articles/2024042801

User Image GemsBot Posted - 2 days ago

6 of 11 $INTC $JNJ $JPM The best reward to risk ratio trades are when consecutive bars show dark colored signals … see 7/11

User Image LieutenantJoe Posted - 2 days ago

$ELTP https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174307311 $JNJ $LLY

User Image NEWBIGTECH Posted - 2 days ago

$AMGN $JNJ $PFE $RHHBY $ENSC

User Image lovablekid Posted - 3 days ago

$JNJ 150+ Coming

User Image NEWBIGTECH Posted - 3 days ago

$ENSC is looking for a partner to help with Opioid Addiction. Has FDA Approval on for its PF614-MPAR® technology. SO Does it get $JNJ $AMGN $PFE or $RHHBY .. Get the word out, maybe competing Bids for this Technology. Who has the made an offer? Are they aware that $ENSC is the only Drug company with this technology?

User Image BarbaraStein Posted - 3 days ago

$SPY $JNJ $PFE $EHC $THC SYRA - call the NFL - Partner with the NFL, NBA, BayHealth, 100s of organizations... Think about that for the weekend and weeks to come SYRA +$50 dd I was watching the NFL draft last night. There was a commercial about NFL helping children and young adults, some with medical needs and others with mental health support SYRA should partner with the NFL A perfect fit and would help millions of people " The NFL and its clubs have supported programs in over 73,000 schools and constructed more than 265 youth fitness zones nationwide—giving more than 38 million children an opportunity to boost their physical activity levels." SYRA easy partnership with the NFL https://www.google.com/search?q=NFL+helps+kids&rlz=1C1SQJL_enUS914US914&oq=NFL+helps+kids&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAIQIRigATIHCAMQIRigATIHCAQQIRigATIHCAUQIRigAdIBCDM2MjNqMGo3qAIAsAIA&sourceid=chrome&ie=UTF-8

User Image sickeconomics Posted - 3 days ago

Tomorrow's Big Pharma, today? $IONS $VRTX $PFE $JNJ $LLY https://www.sickeconomics.com/2024/04/22/ionis-pharmaceuticals-the-little-big-pharma/

User Image PorcoRosso74 Posted - 3 days ago

$JNJ There is really no demand here. Look at Pfizer and BMY how poorly they have been performing for decades...not sure big Pharma is worth any longer

User Image Outcomes Posted - 3 days ago

$PFE $MRNA $JNJ $AZN $NRXP mRNA BAD. '....defense systems are taken down.' TURBO CANCERS "Cancer Resulting From Covid vaccines: Casual Mechanisms, Case Studies, Doctor's Reports-and NIH Coverup" Beware Big pharma. Beware Bureaucrats. https://truth613.substack.com/p/covid-shots-and-cancer-its-real?r=re3i2&utm_medium=ios&triedRedirect=true

User Image Theflash88 Posted - 4 days ago

$BMY $JNJ $LLY $NVO $PFE They need to buy. GLP-1 company like VKTX or ALt..

User Image Nosh Posted - 4 days ago

$JNJ It’s true hedge now against the market…look at that intraday move. Should be fine going forward but goodness that is a big drop for JNJ.

User Image MrMillions19047 Posted - 4 days ago

$PFE $JNJ $BMY Told ya these traditional Pharma stand at the opposite side of weight loss drug companies like $LLY $NVO

User Image LieutenantJoe Posted - 4 days ago

$ELTP elite pharmaceuticals is cash flow positive and profitable. That’s all that needs to be said. In my opinion it’s either going to be bought out north of 1.50 a share or the market capitalization will soon catch up to the fundamentals. $LLY $JNJ

User Image Preacherclint10 Posted - 4 days ago

$AMGN $JNJ $MNKD up up up! Growth!

User Image NEWBIGTECH Posted - 4 days ago

$SNTI clearing IND for SENTI-202, securing strategic collaborations, and reporting financial results. The company focuses on advancing SENTI-202 in the U.S. and SENTI-301A in China, with promising pipeline programs. Financially, Senti Bio holds $35.9 million in cash and expects operations funded into Q1 2025. Buy out candidate? Who? $MRK $JNJ $PFE

User Image Outcomes Posted - 4 days ago

$PFE $MRNA $JNJ $AZN $NRXP 'This is only the beginning.' mRNA BAD. Reparations. Beware Big pharma. https://www.linkedin.com/posts/vejon-health-ltd_the-japanese-people-are-fed-up-with-their-activity-7189243204112683009-ZBKP?utm_source=share&utm_medium=member_desktop

User Image Arooba2 Posted - 4 days ago

$MNKD $JNJ $AMGN i like this way Simple and visual more please

User Image clan Posted - 4 days ago

$MNKD $JNJ $AMGN Don't get your investment advice from an Uber driver. Hear what the pros are saying ...

User Image RealAvidTrader Posted - 4 days ago

$CDTX $VTGN $JNJ

User Image Lionheartleo Posted - 4 days ago

$CYCC squeeze party tomorrow $NVOS $TTOO $JNJ

User Image RealAvidTrader Posted - 4 days ago

$CDTX Stay Humble, Take a Deep Breath And Get Ready For The Rest of The Week. Its Out of Our Hands Now… If (🔑 word) Smart Money, HFs Step on The Gas Here, Watch Out… $JNJ News Could Wake Up The Big Boys 👀 Someone That Sees a Massive Opportunity at These Levels! Huge PR 💪💪 Patience!

Analyst Ratings
HSBC Buy Apr 18, 24
RBC Capital Outperform Apr 17, 24
Cantor Fitzgerald Overweight Apr 17, 24
Morgan Stanley Equal-Weight Apr 17, 24
B of A Securities Neutral Apr 17, 24
Cantor Fitzgerald Overweight Apr 15, 24
Cantor Fitzgerald Overweight Mar 13, 24
RBC Capital Outperform Feb 28, 24
Cantor Fitzgerald Overweight Feb 20, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fasolo Peter Exec VP, Chief HR Of.. Exec VP, Chief HR Officer Jul 25 Sell 170.3249 20,000 3,406,498 102,696 07/27/23
Hait William See Remarks See Remarks Jul 26 Sell 172 14,698 2,528,056 87,747 07/27/23
Hait William See Remarks See Remarks Jul 26 Option 90.44 14,698 1,329,287 102,445 07/27/23
Swanson James D. See Remarks See Remarks Mar 06 Sell 154.6600 1,062 164,199 9,215 03/08/23
McEvoy Ashley EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech Nov 30 Option 72.54 73,323 5,318,850 115,136 12/02/22
McEvoy Ashley EVP, WW Chair, MedTe.. EVP, WW Chair, MedTech Nov 30 Sell 175.77 73,323 12,887,984 41,813 12/02/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Nov 09 Option 72.54 16,410 1,190,381 87,721 11/10/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Nov 09 Sell 173.42 16,410 2,845,822 71,311 11/10/22
Mongon Thibaut Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer Nov 07 Option 108.77 17,043 1,853,767 57,176 11/09/22
Mongon Thibaut Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer Nov 04 Sell 171.18 35,246 6,033,410 40,133 11/08/22
Mongon Thibaut Exec VP, WW Chair, C.. Exec VP, WW Chair, Consumer Nov 04 Option 130.73 35,246 4,607,710 75,379 11/08/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Jun 10 Option 72.54 40,000 2,901,600 111,311 06/14/22
Wengel Kathryn E EVP, Chief GSC Offic.. EVP, Chief GSC Officer Jun 10 Sell 173 40,000 6,920,000 71,311 06/14/22
Decker Robert J Controller, CAO Controller, CAO May 26 Option 72.54 8,462 613,833 23,935 05/31/22
Decker Robert J Controller, CAO Controller, CAO May 26 Sell 180 8,462 1,523,160 15,473 05/31/22
Hait William See Remarks See Remarks Apr 21 Option 90.44 29,699 2,685,978 109,935 04/25/22
Hait William See Remarks See Remarks Apr 21 Sell 183.58 29,699 5,452,142 80,236 04/25/22
Gorsky Alex Director Director Jan 14 Option 65.37 231,951 15,162,637 695,601 01/19/22
Duato Joaquin CEO CEO Jan 14 Option 65.37 84,423 5,518,732 280,475 01/19/22
Sneed Michael E EVP, Global Corp Aff.. EVP, Global Corp Aff & COO Dec 10 Option 62.2 54,662 3,399,976 110,741 12/10/20
Sneed Michael E EVP, Global Corp Aff.. EVP, Global Corp Aff & COO Dec 10 Sell 152.93 54,662 8,359,460 56,079 12/10/20